Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- SymBio, Eagle Take Pfizer Japan to Court after Treakisym Gx Launch
December 27, 2022
- Towa Hopes to Resume Meropenem 0.5 g Shipment in March
December 27, 2022
- AnGes to Invest US$2 Million in Canada’s Vasomune
December 27, 2022
- CureApp to Kick Off Japan PIII Study of Alcohol Addiction Therapeutic App in January
December 27, 2022
- Eisai Begins Data Submission for AD Med Lecanemab in China
December 26, 2022
- Eisai Issues Statement after 3rd Death Potentially Tied to Lecanemab Reported
December 26, 2022
- Shionogi JV, Shanghai Pharma Ink Xocova Import Pact in China
December 26, 2022
- Sanofi Launches Cablivi in Japan for Acquired TTP
December 26, 2022
- Opdivo-Chemo Combo Fails in Asian Adjuvant Study for Gastric Cancer
December 26, 2022
- Yescarta Gets Second-Line Nod for Large B-Cell Lymphoma in Japan
December 26, 2022
- PeptiDream, US Merck Strike Deal on PDC Development
December 23, 2022
- Kaken Subsidiary Hits PII Goal for Vascular Malformation Drug
December 23, 2022
- Janssen Labor Union to Hold 1st Bargaining Session as Early as Jan. 11
December 23, 2022
- Takeda, Mitsubishi, IIF to Operate Shonan iPark under New Joint Firm
December 22, 2022
- Genmab Files Epcoritamab for Large B-Cell Lymphoma in Japan
December 22, 2022
- Padcev/Keytruda Combo Accepted for FDA Review in Bladder Cancer
December 22, 2022
- Livtencity Misses PIII Goal in 1st Line Use for HSCT CMV Infection
December 21, 2022
- Eisai to Divest US Fycompa Rights to Catalyst, Focus on Alzheimer’s R&D
December 21, 2022
- Nippon Shinyaku’s JAK2 Inhibitor Earns Orphan Designation in US
December 21, 2022
- Daiichi Sankyo’s Blood Cancer Drug Ezharmia Now Available
December 21, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…